

Corporate Executive Board

Gabriel Baertschi Chairman of the Corporate Executive Board, Chief Executive Officer



Gabriel Baertschi joined the Grünenthal Group in October 2016 taking over the position of Chairman of the Corporate Executive Board and Chief Executive Officer.

Gabriel Baertschi brings more than 20 years of international experience in the pharmaceutical industry; most of the time he worked for AstraZeneca. Before taking over the position at Grünenthal, he was the country president of Japan (2013 – 2016).

Previously, he served as country president for Germany (2010 – 2012), Thailand (2009 – 2010), and Vietnam (2006 – 2009). Prior to his appointment to senior management, Gabriel Baertschi held various strategic functions in international sales and marketing.

After studying biology at the University of Neuchâtel he started his career as a sales representative in the medical sector for Servier in Switzerland.

Gabriel Baertschi was born in 1974 in Bern/Switzerland.

Contact: Florian Dieckmann, Head Global Communication Tel.: +49 241 569-2555 Email: Florian.Dieckmann@grunenthal.com



Corporate Executive Board

Janneke van der Kamp Member of the Corporate Executive Board, Chief Commercial Officer



In March 2023, Grünenthal welcomed Janneke van der Kamp as Chief Commercial Officer.

Janneke has two decades of experience in the pharmaceutical industry. After beginning her career in consultancy, she joined Switzerland-based pharma company Novartis. Her professional journey has included roles in global product and portfolio strategy as well as country and regional leadership positions. She also has substantial experience

launching and growing brands across several disease areas. Most recently, she served as Head of Pharma Region Europe at Novartis. Janneke's work at Grünenthal is focused on maximising our portfolio, preparing the launch of our pipeline assets, and driving the growth of our key brands.

Before embarking on her business career, Janneke gained a Master of Science in Chemistry from Utrecht University. She also holds a Master of Business Administration from INSEAD. She was born in the Netherlands in 1975.

Contact: Florian Dieckmann, Head Global Communication Tel.: +49 241 569-2555 Email: Florian.Dieckmann@grunenthal.com



Corporate Executive Board

Fabian Raschke Member of the Corporate Executive Board, Chief Financial Officer



In February 2019, Fabian Raschke took over the leadership of Grünenthal's Finance & IT organisation as Chief Financial Officer and Member of the Corporate Executive Board.

From September 2016, he was Head Group Controlling.

Fabian is a senior executive with a wealth of experience in all aspects of finance and its interfaces. Before joining Grünenthal, he worked for the Xella Group. Serving the former Haniel and later private-equity-owned Xella Group for nearly a decade, he

gained experience in various functions, among others leading Controlling as well as Corporate Development. Fabian has extensive experience in due diligence processes, mergers, acquisitions, and post-merger integrations, as well as IPO preparations and placements of bonds on the capital market.

Fabian graduated from the University of Witten/Herdecke in Germany and the University of Buenos Aires, Argentina with a degree in Economics. He was born in Germany in 1977.

Contact: Florian Dieckmann, Head Global Communication Tel.: +49 241 569-2555 Email: Florian.Dieckmann@grunenthal.com



Corporate Executive Board

Jan Adams, Member of the Corporate Executive Board, Chief Scientific Officer



Jan Adams, MD Member of the Corporate Executive Board, Chief Scientific Officer Jan Adams took over the leadership of Grünenthal's R&D organisation as Chief Scientific Officer (CSO) and Member of the Corporate Executive Board in January 2020, after serving as acting CSO since 1 July 2019.

Jan has built up more than 15 years of experience in healthcare and biopharmaceuticals. At Grünenthal, he significantly contributed to working out a concise therapeutic area strategy and led the design and implementation of a future-proof R&D operating model

that can successfully execute the company's strategy – flexible and modality-agnostic while leveraging a strong global network.

Jan joined Grünenthal in July 2017 as Head of Corporate Strategy and Portfolio Management, working at the interface between strategy, research, development, and commercial. Prior to joining Grünenthal, he served in roles with increasing levels of responsibility at Novartis and Takeda, as well as within McKinsey & Company's global Pharmaceutical and Medical Products practice. Jan is a Medical Doctor by training.

He was born in 1977 in Germany.

The portrait photos can be downloaded from the media section on our website: Images | Media | Grünenthal Group (grunenthal.com)

Contact: Florian Dieckmann, Head Global Communication Tel.: +49 241 569-2555 Email: Florian.Dieckmann@grunenthal.com